As of 2024-12-12, the EV/EBITDA ratio of E-Therapeutics PLC (ETX.L) is -2.56. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. ETX.L's latest enterprise value is 24.99 mil GBP. ETX.L's TTM EBITDA according to its financial statements is -9.77 mil GBP. Dividing these 2 quantities gives us the above ETX.L EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 15.7x - 21.3x | 18.2x |
| Forward P/E multiples | 25.4x - 27.6x | 26.8x |
| Fair Price | (34.66) - (28.24) | (30.08) |
| Upside | -485.2% - -413.8% | -434.2% |
| Date | EV/EBITDA |